Analysts Set Gain Therapeutics, Inc. (NASDAQ:GANX) Target Price at $7.50

Shares of Gain Therapeutics, Inc. (NASDAQ:GANX) have received a consensus rating of “Moderate Buy” from the six brokerages that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $7.50.

A number of analysts have issued reports on GANX shares. Roth Capital reiterated a “buy” rating on shares of Gain Therapeutics in a report on Tuesday, May 12th. Oppenheimer reissued an “outperform” rating on shares of Gain Therapeutics in a report on Wednesday, May 27th. Weiss Ratings downgraded Gain Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 9th. Wall Street Zen upgraded Gain Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, June 21st. Finally, BTIG Research restated a “buy” rating and set a $5.00 price target on shares of Gain Therapeutics in a report on Tuesday, June 30th.

Gain Therapeutics Stock Up 6.3%

NASDAQ GANX opened at $1.86 on Tuesday. The stock’s 50 day moving average is $1.79 and its 200 day moving average is $1.96. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.02. Gain Therapeutics has a 12 month low of $1.41 and a 12 month high of $4.34. The stock has a market cap of $79.33 million, a PE ratio of -3.21 and a beta of 0.15.

Gain Therapeutics (NASDAQ:GANX) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.13). During the same quarter in the previous year, the business earned ($0.16) EPS. Research analysts predict that Gain Therapeutics will post -0.54 EPS for the current fiscal year.

Institutional Investors Weigh In On Gain Therapeutics

Several large investors have recently bought and sold shares of GANX. Marshall Wace LLP increased its holdings in shares of Gain Therapeutics by 849.3% in the 4th quarter. Marshall Wace LLP now owns 1,662,293 shares of the company’s stock worth $5,353,000 after buying an additional 1,487,186 shares during the last quarter. Potomac Capital Management Inc. purchased a new position in Gain Therapeutics in the fourth quarter worth about $3,252,000. Geode Capital Management LLC raised its position in Gain Therapeutics by 15.6% during the fourth quarter. Geode Capital Management LLC now owns 397,942 shares of the company’s stock valued at $1,282,000 after purchasing an additional 53,796 shares during the period. Jane Street Group LLC lifted its stake in shares of Gain Therapeutics by 234.5% in the 4th quarter. Jane Street Group LLC now owns 242,328 shares of the company’s stock valued at $780,000 after purchasing an additional 169,878 shares during the last quarter. Finally, State Street Corp lifted its stake in shares of Gain Therapeutics by 72.9% in the 4th quarter. State Street Corp now owns 157,537 shares of the company’s stock valued at $507,000 after purchasing an additional 66,400 shares during the last quarter. Institutional investors own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.